Physicians will ask you what the July panel means. Most of what has been written about it is wrong in a specific, checkable way.
The gap between what an advisory committee did and what the trade press said it did is where an MSL either builds credibility or loses it.
Six of seven peptides were recommended for the 503A bulks list on narrow margins. The committee is advisory, its votes are non-binding, nothing has been added to any list, and no rule has been proposed. Anyone telling a clinic that BPC-157 is now FDA-cleared is wrong.
Plain-language analysis of each compounding development, including the July 2026 vote and what it does and does not permit. Written to be quoted accurately in a physician conversation.
Which compounds sit where, what Category 1 and Category 2 status mean, and why the distinction decides what a pharmacy can legally prepare.
74 protocol sheets with citations, so a question about mechanism does not end with an offer to follow up by email.
Full access to the protocol reference, compliance guides and regulatory briefings.
Get Professional access → Or see everything that is included